ArticleCancer reports (Hoboken, N.J.)2025
Real-World Response and Survival Outcomes and Treatment Patterns in Patients With Extensive Stage Small-Cell Lung Cancer Receiving Third-Line Treatment.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- IAR025, a novel anti-DLL3 x CD3-bispecific antibody, displays high antitumor efficacy in preclinical models of small-cell lung cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Real-World Evidence of Treatment Outcomes in Small Cell Lung Cancer: A Bayesian Mixed Effects and Competitive Risk Approach.JMIR cancer · 2026Article
- Real-World Response and Survival Outcomes and Treatment Patterns in Patients With Extensive Stage Small-Cell Lung Cancer Receiving Third-Line Treatment.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPatients with small-cell lung cancer (SCLC) primarily present with extensive stage (ES) disease and poor 5-year survival. There are few treatment options and limited data on outcomes in third-line (3L) ES SCLC to quantify unmet medical needs. This chart review evaluated real-world (RW) clinical outcomes and treatment patterns in these patients.
methodsThis retrospective study using electronic medical records included adult patients with ES SCLC (≥ 2 claims for metastasized lung cancer) who received ≥ 3 lines of therapy (LOT) at Cancer Treatment Centers of America (now City of Hope). Patients with other/multiple primary malignancies, non-SCLC histology, or treated through a clinical trial were excluded. Clinical outcomes included RW physician-reported response rates, duration of response (DOR), duration of clinical benefit (DoCB), overall survival (OS), and progression-free survival (PFS), stratified by platinum sensitivity and Eastern Cooperative Oncology Group performance status (ECOG-PS). Time-to-event outcomes were estimated via Kaplan-Meier. Treatment patterns were assessed, including the sequence of regimens by LOT and first-line (1L) platinum sensitivity status.
resultsAmong 113 eligible patients (median age 58 years), 54% were female, and 46% had a chemotherapy-free interval after 1L of < 90 days. Tumor shrinkage, complete response, and stable disease were reported in 19%, 1%, and 13% of patients at 3L, respectively. The median DOR, DoCB, OS, and PFS were 2.8, 2.5, 5.8, and 2.4 months in 3L, respectively. Platinum-resistant versus sensitive patients in 1L had shorter time-to-event outcomes. Clinical outcomes were similar regardless of ECOG-PS status. Platinum-based chemotherapy rates decreased from 94% and 93% in 1L to 17% and 16% in 3L in platinum-sensitive and resistant patients, respectively.
conclusionThese RW findings validate 3L results from clinical trials, demonstrating the limited clinical benefits with current therapies in 3L ES SCLC, and highlighting the urgent need for novel therapies that improve outcomes in this difficult-to-treat patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.